Delivery Order SPE2DB25D2204-SPE2DB25FTGVN
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a standard...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injectables, with performance through August 15, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery will be performed at AmerisourceBergen's corporate...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $18,748.72 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of September 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors. This competitive award, issued on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price transaction under a non-set-aside procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 21, 2025, for TEZSPIRE 210 mg/1.91 mL pen auto-injectors. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of August 11, 2025. The contract will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors with an ultimate completion date of September 11, 2025. This competitive award was issued under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injectors on July 24, 2025, with completion targeted for August 14, 2025. This firm fixed-price contract is non-set-aside and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. This award is...
- The Defense Logistics Agency (DLA) awarded a $14,061.54 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pens on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price contract utilizes no set-aside designation and represents a competitively awarded delivery order under the company's existing indefinite delivery contract with DLA. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of August 11, 2025. This non-set-aside contract was competitively awarded on July 21, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE is a specialty biologic medication used in the treatment of moderate-to-severe asthma, reflecting DLA's ongoing...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGVNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injections on August 5, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare programs worldwide through this prime contract vehicle. TEZSPIRE is a biologic treatment for severe eosinophilic asthma, reflecting the company's portfolio of specialty medications supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/5/25 |